DDrare: Database of Drug Development for Rare Diseases

Searched query = "Hypoparathyroidism", "Accessory thyroid hypergasia disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 100mcg rhPTH(1-84); 25mcg rhPTH(1-84); 50mcg rhPTH(1-84); A: PTH (1-84); Acetate; Alfacalcidol; Amorphous calcium carbonate; Betamethasone; CLTX-305; Calcitriol; Calcitriol & Calcium; Calcium; Calcium Carbonate; Calcium Citrate; Calcium carbonate; Calcium carbonate and alphacalcidol; Calcium citrate; Calcium gluconate; Calcium lactate; Carbonate; Combination Product: TransCon PTH; Combination product (Natpara) and drug or supplements [Disease and drug registry]; Crystalline calcium supplements; Dexamethasone; Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland).; Diagnostic Test: Postoperative laboratory blood tests at 24 hour; Diagnostic Test: Postoperative laboratory blood tests at 6 hour; Diagnostic Test: Postoperative laboratory drainage fluid tests at 24 hour; Diagnostic Test: Preoparative blood laboratory tests; EB612 (EBP05); ESIDREX-R; ESIDREX-R 25 mg; EnteraBio's Oral Parathyroid Hormone (1-34); Esidrex; Ether; FORSTEO; FORSTEO-R; Forsteo; Human recombinant parathyroid Hormone; Human recombinant parathyroid hormone; Hydrochlorothiazide; INDOCYANINE GREEN; INN Parathyroid Hormone (1-84) human; Immediate post operative bioassay of Parathyroid Hormone; Indocyanine Green; Indocyanine green; Magnesium; NATPARA/NATPAR; NPSP 558; NPSP558; Natpar; Natpara; Open-label PTH(1-84); Other: Empiric use of Calcium Carbonate and Calcitriol; Other: PTH based Calcium Carbonate and Calcitriol repletion; Other: Postoperative nausea and vomiting at 24 hour; Other: Postoperative nausea and vomiting at 6 hour; Other: Postoperative pain at 24 hour; Other: Postoperative pain at 6 hour; Other: Postoperative sore throat and hoarseness at 24 hour; Other: Postoperative sore throat and hoarseness at 6 hour; Other: Serum calcium concentrations results; Other: Symptomatic hypocalcaemia at 24 hour; Other: Symptomatic hypocalcaemia at 6 hour; PARATHYROID HORMONE; PCO371; POLY(OXY-1,2-ETHANEDIYL), A; POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2-[[6-[[1-[3-[[3-(2,3-DIHYDROXYPROPOXY)PROPYL]AMINO]-3-OXOPROPYL]-2,5-DIOXO-3-PYRROLIDINYL]THIO]HEXYL]AMINO]ETHYL]AMINO]CARBONYL]-2-METHYLALANYL-TERIPARATIDE (2:1); PREOTACT; PTH; PTH 1-34; PTH1-84 in parent study; Parathyroid; Parathyroid Hormone; Parathyroid Hormone (1-84) Human Recombinant; Parathyroid Hormone (rDNA); Parathyroid hormon 1-84; Parathyroid hormone; Parathyroid hormone (rdna); Parathyroideahormon; Phosphate; Phosphate and betamethasone acetate, 2 mL.; Polyethylene glycol; Potassium; Potassium sparing diuretic; Preotact; Procedure: Total thyroidectomy; RECOMBINANT HUMAN PARATHYROID HORMONE (1-84); Rcombinant Human Parathyroid Hormone [rhPTH(1-84)]; Recombinant Human Parathyroid Hormone [rhPTH(1-84)]; RhPTH; RhPTH (1-84); RhPTH(1-84); SUB21634; Saline 0.9% NaCl; Sevelamer; Sodium citrate; Synthetic Human Parathyroid Hormone 1-34; TERIPARATIDE; Teriparatide; Teriparatide conjugated to a multiarm polyethylene glycol carrier molecule through a cleavable linker; Thiazide; Thymus/Parathyroid Transplantation; TransCon PTH; TransCon PTH high-dose pen; TransCon PTH low-dose pen; TransCon PTH mid-dose pen; Tériparatide; UN-ALPHA-R; UN-ALPHA-R 0.25µg; Verde de Indocianina (Indocyanine Green); Vitamin D

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03425747 (ClinicalTrials.gov)	October 15, 2019	27/1/2018	Efficacy of Calcium Citrate Versus Calcium Carbonate for the Management of Chronic Hypoparathyroidism	CALCIUM CITRATE vs CALCIUM CARBONATE FOR THE MANAGEMENT OF CHRONIC HYPOPARATHYROIDISM	Chronic Hypoparathyroidism	Drug: Calcium Carbonate;Drug: Calcium Citrate	Campus Bio-Medico University	NULL	Completed	18 Years	75 Years	All	26	Phase 4	Italy
2	NCT03249012 (ClinicalTrials.gov)	September 1, 2017	9/8/2017	Quality of Life Related to Different Treatment Protocols for Post-thyroidectomy Hypoparathyroidism	Comparing the Quality of Life Associated With Empiric Calcium Repletion and Parathormone (PTH) Based Calcium Repletion for Post Thyroidectomy Hypoparathyroidism	Hypoparathyroidism Postprocedural;Quality of Life	Other: Empiric use of Calcium Carbonate and Calcitriol;Other: PTH based Calcium Carbonate and Calcitriol repletion	CHU de Quebec-Universite Laval	NULL	Recruiting	18 Years	N/A	All	120	N/A	Canada
3	NCT04146259 (ClinicalTrials.gov)	January 1, 2017	29/10/2019	Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism	Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism	Hypoparathyroidism Postprocedural	Drug: calcium carbonate and alphacalcidol	University of Athens	NULL	Completed	19 Years	N/A	Female	109		Greece
4	NCT01815021 (ClinicalTrials.gov)	April 2013	7/3/2013	A Study Comparing Amorphous Calcium Carbonate (ACC) Versus Crystalline Calcium CCS) in Hypoparathyroidism Patients	A Randomized, Two Phase, Adaptive Then Crossover Open-label, Study Comparing Amorphous Calcium Carbonate (ACC) Supplement Versus Commercially Available Crystalline Calcium Supplements (CCS) in the Management of Primary Hypoparathyroidism.	Hypoparathyroidism	Dietary Supplement: amorphous calcium carbonate;Dietary Supplement: crystalline calcium supplements	Amorphical Ltd.	NULL	Completed	18 Years	80 Years	Both	10	Phase 1;Phase 2	Israel
5	JPRN-UMIN000000475	2006/07/01	01/09/2006	Therapeutic strategy of relative hypoparathyroidism in hemodialysis patients using sevelamer hydrochloride, with special reference to vitamin D administration		Relative hypoparathyoidism in maintenance hemodialysis patients	Replacement of calcium carbonate with sevelamer hydrochloride as phosphate binder	Hokusetsu ROD Study Group	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	40	Not applicable	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03425747
(ClinicalTrials.gov)

October 15, 2019

27/1/2018

Efficacy of Calcium Citrate Versus Calcium Carbonate for the Management of Chronic Hypoparathyroidism

CALCIUM CITRATE vs CALCIUM CARBONATE FOR THE MANAGEMENT OF CHRONIC HYPOPARATHYROIDISM

Chronic Hypoparathyroidism

Drug: Calcium Carbonate;Drug: Calcium Citrate

Campus Bio-Medico University

NULL

Completed

18 Years

75 Years

All

Phase 4

Italy

NCT03249012
(ClinicalTrials.gov)

September 1, 2017

9/8/2017

Quality of Life Related to Different Treatment Protocols for Post-thyroidectomy Hypoparathyroidism

Comparing the Quality of Life Associated With Empiric Calcium Repletion and Parathormone (PTH) Based Calcium Repletion for Post Thyroidectomy Hypoparathyroidism

Hypoparathyroidism Postprocedural;Quality of Life

Other: Empiric use of Calcium Carbonate and Calcitriol;Other: PTH based Calcium Carbonate and Calcitriol repletion

CHU de Quebec-Universite Laval

NULL

Recruiting

18 Years

N/A

All

120

N/A

Canada

NCT04146259
(ClinicalTrials.gov)

January 1, 2017

29/10/2019

Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism

Hypoparathyroidism Postprocedural

Drug: calcium carbonate and alphacalcidol

University of Athens

NULL

Completed

19 Years

N/A

Female

109

Greece

NCT01815021
(ClinicalTrials.gov)

April 2013

7/3/2013

A Study Comparing Amorphous Calcium Carbonate (ACC) Versus Crystalline Calcium CCS) in Hypoparathyroidism Patients

A Randomized, Two Phase, Adaptive Then Crossover Open-label, Study Comparing Amorphous Calcium Carbonate (ACC) Supplement Versus Commercially Available Crystalline Calcium Supplements (CCS) in the Management of Primary Hypoparathyroidism.

Hypoparathyroidism

Dietary Supplement: amorphous calcium carbonate;Dietary Supplement: crystalline calcium supplements

Amorphical Ltd.

NULL

Completed

18 Years

80 Years

Both

Phase 1;Phase 2

Israel

JPRN-UMIN000000475

2006/07/01

01/09/2006

Therapeutic strategy of relative hypoparathyroidism in hemodialysis patients using sevelamer hydrochloride, with special reference to vitamin D administration

Relative hypoparathyoidism in maintenance hemodialysis patients

Replacement of calcium carbonate with sevelamer hydrochloride as phosphate binder

Hokusetsu ROD Study Group

NULL

Complete: follow-up complete

20years-old

Not applicable

Male and Female

Not applicable

Japan